◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksB › BPCR

BioPharma Credit Ord (BPCR) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

— · DATA UPDATED 2026-08-16

BioPharma Credit Ord (BPCR) operates in the — industry. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, BPCR reported $132M in revenue and $130M in net income.

Interactive charts & full statements →

BPCR Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$132M$124M$110M$184M
Net Income$130M$122M$108M$182M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BPCR Free Cash Flow History

Cash flow2025-12-312024-12-312023-12-312022-12-312021-12-31
Dividends Paid($110M)($175M)($90M)($156M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BPCR Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$1.2B$1.2B$1.4B$1.4B
Total Liabilities$18M$18M$16M$27M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BPCR viewer.

Other Companies in Software & IT Services

← BPACAll “B” companiesBPOP →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.